A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab-Reference-Cited by-同舟云学术

A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab

Published:2015-04-08 Issue:2 Volume:170 Page:208-217
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Clark William F.¹,Rock Gail²,Barth David³,Arnold Donald M.⁴,Webert Kathyrn E.⁵,Yenson Paul R.⁶,Kelton John G.⁷,Li Lihua¹,Foley Steven R.⁸,

Affiliation:

1. Division of Nephrology; Department of Medicine; Western University; London ON Canada

2. Department of Pathology; University of Ottawa; Ottawa ON Canada

3. Department of Medicine; University of Toronto; Toronto ON Canada

4. Division of Hematology and Thromboembolism; Department of Medicine; McMaster University; Hamilton ON Canada

5. Division of Hematology and Thromboembolism; Department of Medicine and Department of Pathology and Molecular Medicine; McMaster University; Hamilton ON Canada

6. Division of Hematology; Department of Medicine; Vancouver General Hospital; Vancouver BC Canada

7. Department of Pathology and Molecular Medicine; McMaster University; Hamilton ON Canada

8. Division of Clinical Pathology; Department of Pathology and Molecular Medicine; McMaster University; Hamilton ON Canada

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13408/fullpdf

Reference45 articles.

1. The revised CONSORT statement for reporting randomized trials: explanation and elaboration;Altman;Annals of Internal Medicine,2001

2. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange;Bandarenko;Journal of Clinical Apheresis,1998

3. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients;Bell;The New England Journal of Medicine,1991

4. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura;Bianchi;Blood,2002

5. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab;Caramazza;Transfusion,2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group;BLOOD TRANSFUS-ITALY;2024

2. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons;Expert Review of Hematology;2024-02-20

3. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023;International Journal of Hematology;2023-09-10

4. Biomarkers of response and prognosis in TTP;Transfusion and Apheresis Science;2023-04

5. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP);Transfusion Medicine Reviews;2022-10